BOCA RATON, Fla. and MUMBAI, India (PRWEB)
October 14, 2020
Florida Pharmaceutical Products, LLC (FPP), a pharmaceutical company involved in the Development, Sales, Marketing and Distribution of Generic Pharmaceuticals and Indoco Remedies Limited (Indoco), a company engaged in the Development, Manufacturing and Licensing of pharmaceuticals are pleased to announce the signing of an agreement for the Licensing, Supply and Distribution of a USFDA approved ANDA for an Ophthalmic Solution, developed & filed by Indoco and approved by the FDA, scheduled to launch Q1 2021.
The product has sales of approximately $18 million according to IQVIA™. The ANDA product will be sold and distributed by FPP in the FPP Label within the US. “We are excited to work with Indoco on this opportunity and look forward to launching this Ophthalmic product” said Larry J. Lapila, President of FPP. The ANDA will be manufactured by Indoco.
“Indoco is happy to partner with FPP and we will extend our complete support to FPP for gaining market share for this product” said Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd.
About Florida Pharmaceutical:
Florida Pharmaceutical Products, LLC (FPP) is a Boca Raton based pharmaceutical company involved in the development of Generic Pharmaceuticals seeking to gain approval and/or license of niche generic products in a broad range of therapeutic areas for marketing and distribution in the US.
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5,500 people, including more than 300 skilled scientists.
The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities, including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets.
Share article on social media or email: